HI SB473

Exempts drug manufacturers, wholesale prescription drug distributors, and third-party logistics providers from pharmacy license, registration, and permit requirements when distributing dialysate drugs and devices for home dialysis treatment of end-stage renal disease patients.

Requires dialysate drugs and devices to be FDA-approved, lawfully held by registered manufacturers or their agents, and maintained in original sealed packaging from the manufacturing facility.

Mandates that dialysate drugs and devices be delivered only by the manufacturer or manufacturer's agent upon receipt of a physician's order.

Allows delivery directly to patients with end-stage renal disease (or their designees) for self-administration or to healthcare providers and institutions for patient administration of dialysis therapy.

Defines "manufacturer," "wholesale distributor," and "third-party logistics provider" for purposes of the exemption; effective December 31, 2050.